View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	ADPT
Entity Registrant Name	ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key	0001478320
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		126,887,606
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-38957
Entity Tax Identification Number	27-0907024
Entity Address, Address Line One	1551 Eastlake Avenue East
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98102
City Area Code	(206)
Local Phone Number	659-0067
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	WA

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 212,688,000	$ 96,576,000
Short-term marketable securities (amortized cost of $340,952 and $479,791, respectively)	342,485,000	480,290,000
Accounts receivable, net	9,382,000	12,676,000
Inventory	10,518,000	9,069,000
Prepaid expenses and other current assets	9,573,000	14,079,000
Total current assets	584,646,000	612,690,000
Long-term assets
Property and equipment, net	24,952,000	60,355,000
Operating lease right-of-use assets	31,058,000
Long-term marketable securities (amortized cost of $98,847 and $105,263, respectively)	100,618,000	105,435,000
Restricted cash	2,138,000	2,138,000
Intangible assets, net	11,504,000	11,928,000
Goodwill	118,972,000	118,972,000
Other assets	998,000	784,000
Total assets	874,886,000	912,302,000
Current liabilities
Accounts payable	3,895,000	4,453,000
Accrued liabilities	3,804,000	4,371,000
Accrued compensation and benefits	4,177,000	8,124,000
Current portion of deferred rent		371,000
Current operating lease liabilities	1,502,000
Current deferred revenue	64,572,000	60,994,000
Total current liabilities	77,950,000	78,313,000
Long-term liabilities
Deferred rent liability, less current portion		6,918,000
Operating lease liabilities, less current portion	36,545,000
Financing obligation		36,607,000
Deferred revenue, less current portion	208,828,000	219,332,000
Other long-term liabilities		93,000
Total liabilities	323,323,000	341,263,000
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2020 and December 31, 2019; 126,621,829 and 125,238,142 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	12,000	12,000
Additional paid-in capital	945,026,000	935,834,000
Accumulated other comprehensive gain	3,313,000	671,000
Accumulated deficit	(396,788,000)	(365,478,000)
Total shareholders’ equity	551,563,000	571,039,000
Total liabilities and shareholders’ equity	$ 874,886,000	$ 912,302,000

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Amortized cost of short-term marketable securities	$ 340,952	$ 479,791
Amortized cost of long-term marketable securities	$ 98,847	$ 105,263
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock authorized	10,000,000	10,000,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	340,000,000	340,000,000
Common stock issued	126,621,829	125,238,142
Common stock outstanding	126,621,829	125,238,142

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue
Total revenue	$ 20,910,000	$ 12,666,000
Operating expenses
Cost of revenue	5,343,000	4,988,000
Research and development	23,935,000	12,483,000
Sales and marketing	14,007,000	7,817,000
General and administrative	11,821,000	7,004,000
Amortization of intangible assets	424,000	419,000
Total operating expenses	55,530,000	32,711,000
Loss from operations	(34,620,000)	(20,045,000)
Interest and other income, net	2,894,000	1,659,000
Income tax benefit	323,000
Net loss	(31,403,000)	(18,386,000)
Fair value adjustment to Series E-1 convertible preferred stock options		(254,000)
Net loss attributable to common shareholders	$ (31,403,000)	$ (18,640,000)
Net loss per share attributable to common shareholders, basic and diluted	$ (0.25)	$ (1.45)
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted	126,058,389	12,886,087
Sequencing Revenue
Revenue
Total revenue	$ 9,469,000	$ 6,083,000
Development Revenue
Revenue
Total revenue	$ 11,441,000	$ 6,583,000

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Financial Position [Abstract]
Net loss	$ (31,403)	$ (18,386)
Change in unrealized gain on investments	2,642	199
Comprehensive loss	$ (28,761)	$ (18,187)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive (Loss) Gain	Accumulated Deficit
Beginning Balance at Dec. 31, 2018	$ (258,112)		$ 1	$ 37,902	$ (107)	$ (295,908)
Beginning Balance, Shares at Dec. 31, 2018			12,841,536
Convertible preferred stock, Beginning Balance at Dec. 31, 2018		$ 560,858
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2018		92,790,094
Issuance of common stock for cash upon exercise of stock options	33			33
Issuance of common stock for cash upon exercise of stock options, Shares			89,000
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value		$ 98
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares		233,600
Change in redemption value for vested Series E-1 convertible preferred stock options	(254)	$ 254				(254)
Common stock option share-based compensation	3,046			3,046
Other comprehensive income	199				199
Net loss	(18,386)					(18,386)
Convertible preferred stock, Ending Balance at Mar. 31, 2019		$ 561,210
Convertible preferred stock, Ending Balance, Shares at Mar. 31, 2019		93,023,694
Ending Balance at Mar. 31, 2019	(273,474)		$ 1	40,981	92	(314,548)
Ending Balance, Shares at Mar. 31, 2019			12,930,536
Beginning Balance at Dec. 31, 2019	571,039		$ 12	935,834	671	(365,478)
Beginning Balance, Shares at Dec. 31, 2019			125,238,142
Adjustments to accumulated deficit for adoption of guidance on accounting principle	93					93
Issuance of common stock for cash upon exercise of stock options	$ 4,517			4,517
Issuance of common stock for cash upon exercise of stock options, Shares	1,381,437		1,381,437
Vesting of restricted stock units			2,250
Common stock option and restricted stock unit share-based compensation	$ 4,675			4,675
Other comprehensive income	2,642				2,642
Net loss	(31,403)					(31,403)
Convertible preferred stock, Ending Balance, Shares at Mar. 31, 2020		0
Ending Balance at Mar. 31, 2020	$ 551,563		$ 12	$ 945,026	$ 3,313	$ (396,788)
Ending Balance, Shares at Mar. 31, 2020			126,621,829

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Operating activities
Net loss	$ (31,403,000)	$ (18,386,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation expense	1,554,000	1,364,000
Noncash lease expense	631,000
Share-based compensation expense	4,675,000	3,046,000
Intangible assets amortization	424,000	419,000
Investment amortization	(556,000)	(618,000)
Fair value adjustment of convertible preferred stock warrant		18,000
Benefit from income tax	(323,000)		$ 0
Other	114,000
Changes in operating assets and liabilities:
Accounts receivable, net	3,278,000	741,000
Inventory	(1,449,000)	(17,000)
Prepaid expenses and other current assets	3,526,000	(3,732,000)
Accounts payable and accrued liabilities	(4,603,000)	(377,000)
Deferred rent		(235,000)
Operating lease liabilities	(333,000)
Deferred revenue	(6,926,000)	296,080,000
Other	(215,000)
Net cash (used in) provided by operating activities	(31,606,000)	278,303,000
Investing activities
Purchases of property and equipment	(2,963,000)	(3,831,000)
Purchases of marketable securities	(107,747,000)	(270,860,000)
Proceeds from sales and maturities of marketable securities	253,469,000	52,515,000
Net cash provided by (used in) investing activities	142,759,000	(222,176,000)
Financing activities
Proceeds from exercise of stock options	4,959,000	130,000
Other		(6,000)
Net cash provided by financing activities	4,959,000	124,000
Net increase in cash, cash equivalents and restricted cash	116,112,000	56,251,000
Cash, cash equivalents and restricted cash at beginning of year	98,714,000	55,091,000	55,091,000
Cash, cash equivalents and restricted cash at end of period	214,826,000	111,342,000	$ 98,714,000
Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities	627,000	423,000
Deferred offering costs included in accounts payable and accrued expenses		$ 1,825,000
Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases	$ 36,607,000

Organization and Description of Business

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Description of Business

1.	Organization and Description of Business

Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our immune medicine platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from academic and biopharmaceutical customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the Food and Drug Administration (“FDA”) for the detection and monitoring of minimal residual disease (“MRD”) in patients with select blood cancers.

We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

Initial Public Offering

Our registration statement on Form S-1 related to our initial public offering was declared effective on June 26, 2019, and our common stock began trading on the Nasdaq Global Select Market on June 27, 2019. On July 1, 2019, we completed our initial public offering in which we issued and sold 17,250,000 shares of common stock, including shares issued upon the exercise in full of the underwriters’ over-allotment option, at a public offering price of $20.00 per share.

Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Significant Accounting Policies

2.	Significant Accounting Policies

Basis of Presentation and Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

Unaudited Interim Condensed Financial Statements

In our opinion, the accompanying unaudited condensed financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments are of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

The accompanying unaudited condensed financial statements should be read in conjunction with our audited financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on February 26, 2020.

Restricted Cash

We are required to maintain certain balances under lease arrangements for our property and facility leases. We had restricted cash of $2.1 million as of March 31, 2020 and December 31, 2019.

Leases

We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below.

Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.

We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.

Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.

Concentrations of Risk

We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.

Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions.

Significant customers are those which represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the periods presented were as follows:

Revenue

Accounts Receivable, Net

Three Months Ended March 31,

March 31,

December 31,

2020

2019

2020

2019

Customer A

22.0%

41.8%

Customer D

13.7

Genentech, Inc.

54.4

49.8

* less than 10%

Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”), Revenue from Contracts with Customers. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications.

Overview

Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we allocate revenue based on the nature of the performance obligation and the allocated transaction price.

Sequencing Revenue

Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our immunoSEQ and clonoSEQ products and services to our research and clinical customers, respectively.

For research customers, contracts typically include an amount billed in advance of services (“upfront”), and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.

For other research customers who choose to purchase a research use only kit, the kits are sold on a price per kit basis with amounts payable upon delivery of the kit. Payments received are recorded as deferred revenue. For these customers, we have identified one performance obligation: the delivery of sample results. We recognize revenue as the results are delivered to the customer based on a proportion of the estimated samples that can be reported on for each kit.

For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions, commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience.

In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network (“NCCN”) guidelines for longitudinal monitoring in multiple myeloma (“MM”) and B cell acute lymphoblastic leukemia (“ALL”). We bill Medicare for an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue is recognized at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient’s treatment cycle.

Development Revenue

We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of our proprietary immunoSEQ and clonoSEQ services in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers’ regulatory submission as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract, and they are accounted for as a single performance obligation.

When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress based and regulatory milestones is estimated using the most likely amount method where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks that must be managed, as well as the level of effort and investment required to achieve the respective milestone.

The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.

Net Loss Per Share Attributable to Common Shareholders

We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.

Prior to the closing of our initial public offering in July 2019 and the conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the two-class method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective January 1, 2020 using the optional transition method described in ASU 2018-11, Leases (Topic 842) Targeted Improvements. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, Leases (“ASC 840”).

In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of 1) whether any expired or existing contracts are or contain leases; 2) lease classification of expired or existing leases; and 3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our right-of-use assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.

The standard had a material impact on our unaudited condensed balance sheets but did not have a material impact on our unaudited condensed statements of operations or unaudited condensed statements of cash flows. The most significant impact was the recognition of $33.0 million and $39.7 million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $36.6 million asset and corresponding liability previously recorded pursuant to build-to-suit lease guidance under ASC 840, which resulted in an increase to retained earnings of $0.1 million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $7.3 million of deferred rent recognized as of December 31, 2019, as well as a $0.5 million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. Refer to Note 8 of the accompanying notes to our unaudited condensed financial statements for additional information regarding leases.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the unaudited condensed balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security’s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective January 1, 2020. Given the short-term nature of our accounts receivables, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss; therefore, a credit allowance was not recognized.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other: Internal-Use Software (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective January 1, 2020 on a prospective basis, and the adoption did not have any impact on our financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on January 1, 2020 and the adoption did not have a material impact on our financial statements.

Revenue

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenue

MRD Development Agreements

We have entered into agreements with biopharmaceutical customers to further develop and commercialize clonoSEQ and the biopharmaceutical customers’ therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress milestones or achievement of certain regulatory milestones pertaining to the customers’ therapeutic and our clonoSEQ test.

Under the contracts, we identify performance obligations, which may include: (1) obligations to provide services supporting the customer’s regulatory submission activities as they relate to our clonoSEQ test; and (2) sequencing services for customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrained any consideration related to the regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. We recognize revenue relating to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered and when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method based on estimates of effort completed using a cost-based model.

We recognized $0.4 million and $0.3 million in development revenue related to these contracts during the three months ended March 31, 2020 and 2019, respectively.

As of March 31, 2020, in future periods we could receive up to an additional $233.0 million in milestone payments if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our clonoSEQ test.

Genentech Collaboration Agreement

In December 2018, we entered into a worldwide collaboration and license agreement (“Genentech Agreement”) with Genentech to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use T cell receptors (“TCRs”) screened by our immune medicine platform to engineer and manufacture cellular medicines:

•

Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”).

•

Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”).

Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, Collaborative Arrangements (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.

In applying ASC 606, we identified the following performance obligations at the inception of the agreement:

License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology.

License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology.

License to utilize all private antigen TCR product data in connection with research and development activities in the field of use.

License to existing shared antigen data packages.

Research and development services for shared product development including expansion of shared antigen data packages.

Research and development services for private product development.

Obligations to participate on various joint research, development and project committees.

We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.

Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty as a result of the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.

We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of March 31, 2020. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.

As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Product and Personalized Product pathways. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Product and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.

We recognized revenue of $10.9 million and $6.3 million during the three months ended March 31, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

4.	Fair Value Measurements

The following tables set forth the fair value of financial assets as of March 31, 2020 and December 31, 2019 that were measured at fair value on a recurring basis (in thousands):

	March 31, 2020
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	191,213	$	—	$	—	$	191,213
Commercial paper		—		58,793		—		58,793
U.S. government debt and agency securities		—		368,450		—		368,450
Corporate bonds		—		27,860		—		27,860
Total financial assets	$	191,213	$	455,103	$	—	$	646,316

	December 31, 2019
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	88,683	$	—	$	—	$	88,683
Commercial paper		—		121,867		—		121,867
U.S. government debt and agency securities		—		377,243		—		377,243
Corporate bonds		—		86,615		—		86,615
Total financial assets	$	88,683	$	585,725	$	—	$	674,408

Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities, commercial paper and corporate bonds, and are valued based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Of the March 31, 2020 Level 2 U.S. government debt and agency securities balance, $12.0 million is recorded as cash and cash equivalents on our unaudited condensed balance sheet.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Investments

5.	Investments

Available-for-sale investments consisted of the following as of March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
Short-term marketable securities
Commercial paper	$	58,793	$	—	$	—		$	58,793
U.S. government debt and agency securities		266,378		1,532		—			267,910
Corporate bonds		15,781		12		(11	)		15,782
Total short-term marketable securities	$	340,952	$	1,544	$	(11	)	$	342,485
Long-term marketable securities
U.S. government debt and agency securities	$	86,861	$	1,679	$	—		$	88,540
Corporate bonds		11,986		108		(16	)		12,078
Total long-term marketable securities	$	98,847	$	1,787	$	(16	)	$	100,618

	December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
Short-term marketable securities
Commercial paper	$	121,866	$	—	$	—		$	121,866
U.S. government debt and agency securities		285,963		394		(1	)		286,356
Corporate bonds		71,962		109		(3	)		72,068
Total short-term marketable securities	$	479,791	$	503	$	(4	)	$	480,290
Long-term marketable securities
U.S. government debt and agency securities	$	90,750	$	146	$	(9	)	$	90,887
Corporate bonds		14,513		35		—			14,548
Total long-term marketable securities	$	105,263	$	181	$	(9	)	$	105,435

All the commercial paper, U.S. government debt and agency securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective balance sheet date.

Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivables of $1.9 million and $2.2 million were presented separately within the prepaid expenses and other current assets line item on our unaudited condensed balance sheets as of March 31, 2020 and December 31, 2019, respectively. We have made an accounting policy election to not measure an allowance for credit losses for accrued interest receivables.

The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time that individual securities have been in a continuous loss position, as of March 31, 2020 (in thousands):

	Less Than 12 Months					12 Months Or Greater
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
Corporate bonds	$	5,767	$	(27	)	$	—	$	—
Total available-for-sale securities	$	5,767	$	(27	)	$	—	$	—

We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.

As of March 31, 2020, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis. Based on our assessment, we concluded all impairment as of March 31, 2020 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment for our available-for-sale securities was recorded in other comprehensive loss.

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

6.	Goodwill and Intangible Assets

There have been no changes in the carrying amount of goodwill since its recognition in 2015.

Intangible assets subject to amortization as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands):

	March 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(8,717	)	$	11,283
Purchased intellectual property		325		(104	)		221
Balance at March 31, 2020	$	20,325	$	(8,821	)	$	11,504

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(8,301	)	$	11,699
Purchased intellectual property		325		(96	)		229
Balance at December 31, 2019	$	20,325	$	(8,397	)	$	11,928

The developed technology was acquired in connection with our acquisition of Sequenta, Inc. (“Sequenta”) in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 6.8 years.

As of March 31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):

2020 (excluding the three months ended March 31, 2020)	$	1,279
2021		1,699
2022		1,699
2023		1,699
2024		1,703
Thereafter		3,425
Total future amortization expense	$	11,504

Deferred Revenue

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Deferred Revenue

7.	Deferred Revenue

Deferred revenue by revenue classification as of March 31, 2020 and December 31, 2019 was as follows (in thousands):

	March 31, 2020		December 31, 2019
Current deferred revenue
Sequencing	$	13,565	$	12,482
Development		51,007		48,512
Total current deferred revenue		64,572		60,994
Non-current deferred revenue
Sequencing		1,241		1,459
Development		207,587		217,873
Total non-current deferred revenue		208,828		219,332
Total current and non-current deferred revenue	$	273,400	$	280,326

Genentech deferred revenue represents $50.0 million and $204.0 million of the current and non-current development deferred revenue balances, respectively, at March 31, 2020 and $48.1 million and $216.8 million of the current and non-current development deferred revenue balances, respectively, at December 31, 2019. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately six to seven years. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.

Changes in deferred revenue during the three months ended March 31, 2020 were as follows (in thousands):

Deferred revenue balance at December 31, 2019	$	280,326
Additions to deferred revenue during the period		7,198
Revenue recognized during the period		(14,124	)
Deferred revenue balance at March 31, 2020	$	273,400

As of March 31, 2020, $13.1 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2019. As a result of cancelled customer sequencing contracts, we recognized $0.4 million of sequencing revenue during the three months ended March 31, 2020.

Leases

3 Months Ended

Mar. 31, 2020

Lessee Disclosure [Abstract]

Leases

We have operating lease agreements for the laboratory and office facilities that we occupy in Seattle, Washington and South San Francisco, California, as well as server space. As of March 31, 2020, we were not party to any finance leases. Our leases have remaining terms of 2.1 years to 12.3 years, and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of March 31, 2020, it was reasonably certain that we would exercise our option to terminate one of our leases after 3.0 years.

Other information related to our operating leases as of March 31, 2020 was as follows:

Weighted-average remaining lease term (in years)			11.16
Weighted-average discount rate			4.5	%

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of March 31, 2020 (in thousands):

2020 (excluding the three months ended March 31, 2020)	$	3,298
2021		5,123
2022		5,074
2023		4,364
2024		4,326
Thereafter		28,771
Total undiscounted lease payments		50,956
Less:
Imputed interest rate		(11,315	)
Tenant improvement receivables		(1,594	)
Total operating lease liabilities	$	38,047
Less: current portion		(1,502	)
Operating lease liabilities, less current portion	$	36,545

Operating lease expense was $1.1 million for the three months ended March 31, 2020. Variable lease expense for operating leases was $0.5 million for the three months ended March 31, 2020. Rent expense recognized under ASC 840, inclusive of operating and maintenance costs, was $1.2 million during the three months ended March 31, 2019.

Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2020 was $0.8 million, net of $0.3 million of cash received for tenant improvement allowances.

Leases Not Yet Commenced

In August 2019, we entered into an agreement to rent 100,000 square feet in a to-be-constructed building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our significant involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet for the cost of the building was derecognized upon adoption of ASC 842.

As of March 31, 2020, we were party to other leases that had not yet commenced pursuant to ASC 842, including a new amendment to our existing lease in South San Francisco, California to rent 19,867 additional square feet, which provides for a $0.6 million tenant improvement allowance.

Pursuant to the guidance in ASC 842, these leases will be assessed for classification and a lease liability and corresponding right-of-use asset will be recorded upon lease commencement, which may be delayed due to the impact of the COVID-19 pandemic. Future non-cancellable undiscounted lease payments associated with signed leases that have not yet commenced total $100.1 million, payable over lease terms ranging from 5.2 years to 12.7 years.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.	Commitments and Contingencies

Legal Proceedings

We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We are not currently party to any material legal proceedings.

Indemnification Agreements

In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

Shareholders' Equity

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Shareholders' Equity

10.	Shareholders’ Equity

Convertible Preferred Stock

Immediately prior to the completion of our initial public offering on July 1, 2019, 93,039,737 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock. As of March 31, 2020, no shares of convertible preferred stock were outstanding.

Preferred Stock

We are authorized to issue 10,000,000 shares of preferred stock, par value $0.0001 per share. As of March 31, 2020, no shares of preferred stock were outstanding.

Common Stock

We are authorized to issue 340,000,000 shares of common stock. Our common stock has a par value of $0.0001, no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of March 31, 2020, we had 126,621,829 shares of common stock outstanding.

We have reserved shares of common stock for the following as of March 31, 2020:

Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted			17,492,204
Shares available for future grant under the 2019 Equity Incentive Plan			19,433,424
Shares available for future grant under the Employee Stock Purchase Plan			2,804,298
Shares to be issued upon exercise of a common stock warrant			56,875
Total shares of common stock reserved for future issuance			39,786,801

Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1.0% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the board of directors.

On January 1, 2020, our 2019 Plan and ESPP reserves automatically increased by 6,261,907 shares and 1,252,381 shares, respectively.

Common Stock Warrants

In 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant is exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1,2019, this convertible preferred stock warrant, which was previously recorded as a financial liability, was converted to a warrant to purchase the same number of shares of common stock. Upon conversion, the financial liability was reclassified to the additional paid-in capital line item on our unaudited condensed balance sheet. The warrant to purchase 56,875 shares of common stock remains outstanding as of March 31, 2020.

Equity Incentive Plans

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Incentive Plans

11.	Equity Incentive Plans

Sequenta 2008 Stock Plan, as amended

In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta’s Equity Incentive Plan (“2008 Plan”), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options are now exercisable for common stock. While no shares are available for future issuance under this plan, the 2008 Plan continues to govern outstanding equity awards granted thereunder.

Adaptive 2009 Equity Incentive Plan

We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date, and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.

2019 Equity Incentive Plan

The 2019 Plan was approved by our shareholders on June 13, 2019 and, pursuant to the resolutions adopted by our board of directors, became effective immediately prior to and contingent upon the closing of our initial public offering. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the grant date of the option, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date, and vesting is established at the time of grant. Except for certain option grants made to non-employee directors, stock options granted under the 2019 Plan generally vest over a four-year period, subject to continuous service through each applicable vesting date. As of March 31, 2020, we have authorized 22,025,259 shares of common stock for issuance under the 2019 Plan.

Changes in shares available for grant during the three months ended March 31, 2020 were as follows:

	Shares Available for Grant
Shares available for grant at December 31, 2019		15,396,254
2019 Plan reserve increase on January 1, 2020		6,261,907
Options and restricted stock units granted		(2,292,847	)
Options and restricted stock units forfeited or cancelled		68,110
Shares available for grant at March 31, 2020		19,433,424

Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the three months ended March 31, 2020 was as follows:

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Options outstanding at December 31, 2019		16,646,654		$	6.14	$	398,379
Options granted		2,292,847			29.68
Options forfeited or cancelled		(68,110	)		8.63
Options exercised		(1,381,437	)		3.27
Options outstanding at March 31, 2020		17,489,954		$	9.44	$	329,432
Options vested and exercisable at March 31, 2020		9,670,591		$	5.03	$	220,010

The weighted-average remaining contractual life for options outstanding at March 31, 2020 was 7.2 years. The weighted-average remaining contractual life for vested and exercisable options outstanding at March 31, 2020 was 5.8 years.

Of the $5.0 million proceeds from exercise of stock options included on our unaudited condensed statements of cash flows for the three months ended March 31, 2020, $0.5 million related to options exercised prior to but settled in the three months ended March 31, 2020.

As of December 31, 2019, 4,500 shares of restricted stock units (“RSUs”), with a weighted-average grant date fair value per share of $41.63, were nonvested and outstanding. We did not grant any shares of RSUs during the three months ended March 31, 2020. During the three months ended March 31, 2020, 2,250 shares of RSUs, with a weighted-average grant date fair value per share of $41.63, vested. As of March 31, 2020, 2,250 shares of RSUs, with a weighted-average grant date fair value per share of $41.63, remained nonvested and outstanding.

Fair Value of Options and Grant Date Fair Value of Restricted Stock Units

The estimated fair value of options granted during the three months ended March 31, 2020 and 2019 was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Three Months Ended March 31,
	2020		2019
Grant date fair value	$17.68 - $31.71		$7.80
Expected term (in years)	5.27 - 6.08		5.27 - 6.08
Risk-free interest rate	0.7% - 1.7%		2.5%
Expected volatility	70.5% - 72.1%		64.3% - 65.5%
Expected dividend yield		—		—

The weighted-average volatility used in the fair value calculations of options granted during the three months ended March 31, 2020 and 2019 was 70.7% and 64.4%, respectively.

The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:

Fair value of common stock—Prior to the closing of our initial public offering, the grant date fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. For valuations of grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant or other relevant determination date, as reported on The Nasdaq Global Select Market.

Expected term—The expected term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, Compensation—Stock Compensation, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the option.

Risk-free interest rate—We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues, with remaining terms similar to the expected term of the options.

Expected volatility—As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of the expected term.

Expected dividend yield—We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model.

The grant date fair value of RSUs granted after the closing of our initial public offering is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

Share-based compensation expense of $4.7 million and $3.0 million was recognized during the three months ended March 31, 2020 and 2019, respectively.

The compensation costs related to stock options and RSUs for the three months ended March 31, 2020 and 2019 are included on our statements of operations as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cost of revenue	$	172	$	130
Research and development		1,544		917
Sales and marketing		1,157		906
General and administration		1,802		1,093
Total share-based compensation expense	$	4,675	$	3,046

At March 31, 2020, unrecognized share-based compensation expense related to unvested stock options was $71.2 million, which is expected to be recognized over a remaining weighted-average period of 3.3 years. Additionally, at March 31, 2020, unrecognized share-based compensation expense related to unvested RSUs was $0.1 million, which is expected to be recognized over a remaining weighted-average period of 0.2 years.

Income Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

12.	Income Taxes

The effective tax benefit was $0.3 million for the three months ended March 31, 2020. There was no effective tax benefit for the year ended December 31, 2019.

We calculate our tax provision by applying a forecasted Annual Effective Tax Rate (“AETR”) against year-to-date pre-tax loss, and taking into account certain discrete items, primarily related to the exercise activity of stock options, in the quarter in which they occur. We recorded a pre-tax benefit for the three months ended March 31, 2020 because the discrete benefit from option exercises is greater than the year-to-date AETR tax expense. We expect to recognize tax expense on a full year basis, inclusive of discrete items.

We file income tax returns in the U.S. federal jurisdiction and various U.S. state jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. Because of net operating loss carryforwards, substantially all tax years since inception remain open to federal and state tax examination.

On March 27, 2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) to provide emergency economic stimulus in light of the effects of COVID-19. While the CARES Act provides extensive tax changes, some of the more significant provisions include removing certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act of 2017 (“TCJA”). We are still evaluating the CARES Act, but do not anticipate a significant impact to our income tax provision.

Net Loss Per Share Attributable to Common Shareholders

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Shareholders

13.	Net Loss Per Share Attributable to Common Shareholders

Net Loss Per Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the three months ended March 31, 2020 and 2019 (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2020			2019
Net loss	$	(31,403	)	$	(18,386	)
Fair value adjustments to redemption value for Series E-1 convertible preferred stock options		—			(254	)
Net loss attributable to common shareholders, basic and diluted	$	(31,403	)	$	(18,640	)
Weighted-average shares used in computing net loss per share		126,058,389			12,886,087
Net loss per share attributable to common shareholders, basic and diluted	$	(0.25	)	$	(1.45	)

Since we were in a loss position for all periods presented, basic net loss per share attributable to common shareholders is the same as diluted net loss per share attributable to common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the three months ended March 31, 2020 and 2019, as they had an anti-dilutive effect:

	Three Months Ended March 31,
	2020		2019
Convertible preferred stock (on as if converted basis)		—		92,974,578
Stock options issued and outstanding		16,823,569		16,190,831
Unvested restricted stock units		3,618		—
Common stock warrants		56,875		55,032
Convertible preferred stock warrants		—		56,875
Total		16,884,062		109,277,316

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation and Use of Estimates

Unaudited Interim Condensed Financial Statements

Restricted Cash

We are required to maintain certain balances under lease arrangements for our property and facility leases. We had restricted cash of $2.1 million as of March 31, 2020 and December 31, 2019.

Leases

Concentrations of Risk

Revenue

Accounts Receivable, Net

Three Months Ended March 31,

March 31,

December 31,

2020

2019

2020

2019

Customer A

22.0%

41.8%

Customer D

13.7

Genentech, Inc.

54.4

49.8

* less than 10%

Revenue Recognition

Overview

Sequencing Revenue

Development Revenue

Net Loss Per Share Attributable to Common Shareholders

Recently Adopted Accounting Pronouncements

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Schedule of Concentrations of Risk Percentage

Revenue

Accounts Receivable, Net

Three Months Ended March 31,

March 31,

December 31,

2020

2019

2020

2019

Customer A

22.0%

41.8%

Customer D

13.7

Genentech, Inc.

54.4

49.8

* less than 10%

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables set forth the fair value of financial assets as of March 31, 2020 and December 31, 2019 that were measured at fair value on a recurring basis (in thousands):

	March 31, 2020
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	191,213	$	—	$	—	$	191,213
Commercial paper		—		58,793		—		58,793
U.S. government debt and agency securities		—		368,450		—		368,450
Corporate bonds		—		27,860		—		27,860
Total financial assets	$	191,213	$	455,103	$	—	$	646,316

	December 31, 2019
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	88,683	$	—	$	—	$	88,683
Commercial paper		—		121,867		—		121,867
U.S. government debt and agency securities		—		377,243		—		377,243
Corporate bonds		—		86,615		—		86,615
Total financial assets	$	88,683	$	585,725	$	—	$	674,408

Investments (Tables)

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Schedule of Available-for-sale Investments

Available-for-sale investments consisted of the following as of March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
Short-term marketable securities
Commercial paper	$	58,793	$	—	$	—		$	58,793
U.S. government debt and agency securities		266,378		1,532		—			267,910
Corporate bonds		15,781		12		(11	)		15,782
Total short-term marketable securities	$	340,952	$	1,544	$	(11	)	$	342,485
Long-term marketable securities
U.S. government debt and agency securities	$	86,861	$	1,679	$	—		$	88,540
Corporate bonds		11,986		108		(16	)		12,078
Total long-term marketable securities	$	98,847	$	1,787	$	(16	)	$	100,618

	December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
Short-term marketable securities
Commercial paper	$	121,866	$	—	$	—		$	121,866
U.S. government debt and agency securities		285,963		394		(1	)		286,356
Corporate bonds		71,962		109		(3	)		72,068
Total short-term marketable securities	$	479,791	$	503	$	(4	)	$	480,290
Long-term marketable securities
U.S. government debt and agency securities	$	90,750	$	146	$	(9	)	$	90,887
Corporate bonds		14,513		35		—			14,548
Total long-term marketable securities	$	105,263	$	181	$	(9	)	$	105,435

Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position

	Less Than 12 Months					12 Months Or Greater
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
Corporate bonds	$	5,767	$	(27	)	$	—	$	—
Total available-for-sale securities	$	5,767	$	(27	)	$	—	$	—

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets Subject to Amortization

Intangible assets subject to amortization as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands):

	March 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(8,717	)	$	11,283
Purchased intellectual property		325		(104	)		221
Balance at March 31, 2020	$	20,325	$	(8,821	)	$	11,504

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(8,301	)	$	11,699
Purchased intellectual property		325		(96	)		229
Balance at December 31, 2019	$	20,325	$	(8,397	)	$	11,928

Schedule of Future Amortization Expense for Intangible Assets

As of March 31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):

2020 (excluding the three months ended March 31, 2020)	$	1,279
2021		1,699
2022		1,699
2023		1,699
2024		1,703
Thereafter		3,425
Total future amortization expense	$	11,504

Deferred Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Schedule of Deferred Revenue by Revenue Classification

Deferred revenue by revenue classification as of March 31, 2020 and December 31, 2019 was as follows (in thousands):

	March 31, 2020		December 31, 2019
Current deferred revenue
Sequencing	$	13,565	$	12,482
Development		51,007		48,512
Total current deferred revenue		64,572		60,994
Non-current deferred revenue
Sequencing		1,241		1,459
Development		207,587		217,873
Total non-current deferred revenue		208,828		219,332
Total current and non-current deferred revenue	$	273,400	$	280,326

Schedule of Changes in Deferred Revenue

Changes in deferred revenue during the three months ended March 31, 2020 were as follows (in thousands):

Deferred revenue balance at December 31, 2019	$	280,326
Additions to deferred revenue during the period		7,198
Revenue recognized during the period		(14,124	)
Deferred revenue balance at March 31, 2020	$	273,400

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Lessee Disclosure [Abstract]

Summary of Oher Information Related to Operating Lease

Other information related to our operating leases as of March 31, 2020 was as follows:

Weighted-average remaining lease term (in years)			11.16
Weighted-average discount rate			4.5	%

Summary of Reconciles Undiscounted Operating Lease Cash Flows

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of March 31, 2020 (in thousands):

2020 (excluding the three months ended March 31, 2020)	$	3,298
2021		5,123
2022		5,074
2023		4,364
2024		4,326
Thereafter		28,771
Total undiscounted lease payments		50,956
Less:
Imputed interest rate		(11,315	)
Tenant improvement receivables		(1,594	)
Total operating lease liabilities	$	38,047
Less: current portion		(1,502	)
Operating lease liabilities, less current portion	$	36,545

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Summary of Reserved Shares of Common Stock

We have reserved shares of common stock for the following as of March 31, 2020:

Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted			17,492,204
Shares available for future grant under the 2019 Equity Incentive Plan			19,433,424
Shares available for future grant under the Employee Stock Purchase Plan			2,804,298
Shares to be issued upon exercise of a common stock warrant			56,875
Total shares of common stock reserved for future issuance			39,786,801

Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Changes in Shares Available for Grant

Changes in shares available for grant during the three months ended March 31, 2020 were as follows:

	Shares Available for Grant
Shares available for grant at December 31, 2019		15,396,254
2019 Plan reserve increase on January 1, 2020		6,261,907
Options and restricted stock units granted		(2,292,847	)
Options and restricted stock units forfeited or cancelled		68,110
Shares available for grant at March 31, 2020		19,433,424

Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan

Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the three months ended March 31, 2020 was as follows:

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Options outstanding at December 31, 2019		16,646,654		$	6.14	$	398,379
Options granted		2,292,847			29.68
Options forfeited or cancelled		(68,110	)		8.63
Options exercised		(1,381,437	)		3.27
Options outstanding at March 31, 2020		17,489,954		$	9.44	$	329,432
Options vested and exercisable at March 31, 2020		9,670,591		$	5.03	$	220,010

Summary of Estimated Fair Value of Options Granted

The estimated fair value of options granted during the three months ended March 31, 2020 and 2019 was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Three Months Ended March 31,
	2020		2019
Grant date fair value	$17.68 - $31.71		$7.80
Expected term (in years)	5.27 - 6.08		5.27 - 6.08
Risk-free interest rate	0.7% - 1.7%		2.5%
Expected volatility	70.5% - 72.1%		64.3% - 65.5%
Expected dividend yield		—		—

Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations

The compensation costs related to stock options and RSUs for the three months ended March 31, 2020 and 2019 are included on our statements of operations as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cost of revenue	$	172	$	130
Research and development		1,544		917
Sales and marketing		1,157		906
General and administration		1,802		1,093
Total share-based compensation expense	$	4,675	$	3,046

Net Loss Per Share Attributable to Common Shareholders (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

	Three Months Ended March 31,
	2020			2019
Net loss	$	(31,403	)	$	(18,386	)
Fair value adjustments to redemption value for Series E-1 convertible preferred stock options		—			(254	)
Net loss attributable to common shareholders, basic and diluted	$	(31,403	)	$	(18,640	)
Weighted-average shares used in computing net loss per share		126,058,389			12,886,087
Net loss per share attributable to common shareholders, basic and diluted	$	(0.25	)	$	(1.45	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the three months ended March 31, 2020 and 2019, as they had an anti-dilutive effect:

	Three Months Ended March 31,
	2020		2019
Convertible preferred stock (on as if converted basis)		—		92,974,578
Stock options issued and outstanding		16,823,569		16,190,831
Unvested restricted stock units		3,618		—
Common stock warrants		56,875		55,032
Convertible preferred stock warrants		—		56,875
Total		16,884,062		109,277,316

Organization and Description of Business - Additional Information (Details) - Initial Public Offering	Jul. 01, 2019 $ / shares shares
Subsidiary Or Equity Method Investee [Line Items]
Shares issued \| shares	17,250,000
Public offering price \| $ / shares	$ 20.00

Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($) Performance_Obligation	Dec. 31, 2019 USD ($)
Significant Accounting Policies [Line Items]
Restricted cash	$ 2,138	$ 2,138
Operating lease right-of-use assets	31,058
Operating lease liabilities	38,047
Accumulated deficit	(396,788)	$ (365,478)
ASU 2016-02 (Topic 842)
Significant Accounting Policies [Line Items]
Operating lease right-of-use assets	33,000
Operating lease liabilities	39,700
Derecognition of deferred rent	7,300
Reclassification of tenant incentive receivables	500
Derecognized portion of build-to-suit asset	36,600
Accumulated deficit	$ 100
Sequencing Revenue
Significant Accounting Policies [Line Items]
Number of revenue performance obligations \| Performance_Obligation	2

Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Customer A \| Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage	22.00%	41.80%
Customer D \| Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage	13.70%
Genentech, Inc. \| Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage	54.40%		49.80%

Revenue - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended
Revenue - Additional Information (Details) - USD ($)	Mar. 31, 2020	Feb. 28, 2019	Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Revenue recognized	$ 13,100,000		$ (14,124,000)
Revenue from collaboration agreement			20,910,000	$ 12,666,000
MRD Development Agreements
Disaggregation Of Revenue [Line Items]
Revenue recognized			400,000	300,000
MRD Development Agreements \| Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable	233,000,000.0		233,000,000.0
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Non-refundable upfront payments received		$ 300,000,000.0	300,000,000.0
Revenue from collaboration agreement			$ 10,900,000	$ 6,300,000
Genentech Collaboration Agreement \| Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period			8 years
Genentech Collaboration Agreement \| Maximum \| Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	75,000,000.0		$ 75,000,000.0
Genentech Collaboration Agreement \| Maximum \| Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	300,000,000.0		300,000,000.0
Genentech Collaboration Agreement \| Maximum \| Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	1,430,000,000.0		1,430,000,000.0
Genentech Collaboration Agreement \| Minimum
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	$ 1,800,000		$ 1,800,000
Revenue recognition expected period			7 years

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Financial assets
Total financial assets	$ 646,316	$ 674,408
Level 1
Financial assets
Total financial assets	191,213	88,683
Level 2
Financial assets
Total financial assets	455,103	585,725
Money Market Funds
Financial assets
Total financial assets	191,213	88,683
Money Market Funds \| Level 1
Financial assets
Total financial assets	191,213	88,683
Commercial Paper
Financial assets
Total financial assets	58,793	121,867
Commercial Paper \| Level 2
Financial assets
Total financial assets	58,793	121,867
U.S. Government Debt and Agency Securities
Financial assets
Total financial assets	368,450	377,243
U.S. Government Debt and Agency Securities \| Level 2
Financial assets
Total financial assets	368,450	377,243
Corporate Bonds
Financial assets
Total financial assets	27,860	86,615
Corporate Bonds \| Level 2
Financial assets
Total financial assets	$ 27,860	$ 86,615

Fair Value Measurements - Additional Information (Details) $ in Millions	Mar. 31, 2020 USD ($)
Level 2 \| U.S. Government Debt and Agency Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 12.0

Investments - Schedule of Available-for-sale Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	$ 340,952	$ 479,791
Unrealized Gain	1,544	503
Unrealized Loss	(11)	(4)
Estimated Fair Value	342,485	480,290
Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	98,847	105,263
Unrealized Gain	1,787	181
Unrealized Loss	(16)	(9)
Estimated Fair Value	100,618	105,435
Commercial Paper \| Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	58,793	121,866
Estimated Fair Value	58,793	121,866
U.S. Government Debt and Agency Securities \| Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	266,378	285,963
Unrealized Gain	1,532	394
Unrealized Loss		(1)
Estimated Fair Value	267,910	286,356
U.S. Government Debt and Agency Securities \| Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	86,861	90,750
Unrealized Gain	1,679	146
Unrealized Loss		(9)
Estimated Fair Value	88,540	90,887
Corporate Bonds \| Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	15,781	71,962
Unrealized Gain	12	109
Unrealized Loss	(11)	(3)
Estimated Fair Value	15,782	72,068
Corporate Bonds \| Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	11,986	14,513
Unrealized Gain	108	35
Unrealized Loss	(16)
Estimated Fair Value	$ 12,078	$ 14,548

Investments - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
Schedule of Available-for-Sale Securities [Line Items]
Accrued interest receivable	$ 1.9	$ 2.2

Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	$ 5,767
Less than 12 months, Unrealized loss	(27)
Corporate Bonds
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	5,767
Less than 12 months, Unrealized loss	$ (27)

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Goodwill [Line Items]
Goodwill	$ 118,972,000	$ 118,972,000	$ 0
Purchased Intellectual Property
Goodwill [Line Items]
Amortization period of intangible assets	6 years 9 months 18 days

Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 20,325	$ 20,325
Accumulated Amortization	(8,821)	(8,397)
Net Carrying Amount	11,504	11,928
Acquired Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	20,000	20,000
Accumulated Amortization	(8,717)	(8,301)
Net Carrying Amount	11,283	11,699
Purchased Intellectual Property
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	325	325
Accumulated Amortization	(104)	(96)
Net Carrying Amount	$ 221	$ 229

Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
2020 (excluding the three months ended March 31, 2020)	$ 1,279
2021	1,699
2022	1,699
2023	1,699
2024	1,703
Thereafter	3,425
Net Carrying Amount	$ 11,504	$ 11,928

Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current deferred revenue
Total current deferred revenue	$ 64,572	$ 60,994
Non-current deferred revenue
Total non-current deferred revenue	208,828	219,332
Total current and non-current deferred revenue	273,400	280,326
Sequencing Revenue
Current deferred revenue
Total current deferred revenue	13,565	12,482
Non-current deferred revenue
Total non-current deferred revenue	1,241	1,459
Development Revenue
Current deferred revenue
Total current deferred revenue	51,007	48,512
Non-current deferred revenue
Total non-current deferred revenue	$ 207,587	$ 217,873

Deferred Revenue - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Current deferred revenue	$ 64,572	$ 64,572	$ 60,994
Deferred revenue, less current portion	208,828	208,828	219,332
Revenue recognized	13,100	(14,124)
Development Revenue
Disaggregation Of Revenue [Line Items]
Current deferred revenue	51,007	51,007	48,512
Deferred revenue, less current portion	207,587	207,587	217,873
Development Revenue \| Genentech, Inc.
Disaggregation Of Revenue [Line Items]
Current deferred revenue	50,000	50,000	48,100
Deferred revenue, less current portion	204,000	204,000	216,800
Sequencing Revenue
Disaggregation Of Revenue [Line Items]
Current deferred revenue	13,565	13,565	12,482
Deferred revenue, less current portion	$ 1,241	1,241	$ 1,459
Revenue recognized		$ 400

Deferred Revenue - Additional Information (Details1) - Genentech, Inc. - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-04-01	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	12 months
Minimum
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	6 years
Maximum
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	7 years

Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 31, 2020	Mar. 31, 2020
Revenue From Contract With Customer [Abstract]
Deferred revenue balance at December 31, 2019		$ 280,326
Additions to deferred revenue during the period		7,198
Revenue recognized during the period	$ 13,100	(14,124)
Deferred revenue balance at March 31, 2020	$ 273,400	$ 273,400

Leases- Additional Information (Details) $ in Millions	3 Months Ended
Leases- Additional Information (Details) $ in Millions	Mar. 31, 2020 USD ($) ft² Lease	Mar. 31, 2019 USD ($)	Aug. 31, 2019 USD ($) ft²
Lessee Lease Description [Line Items]
Operating lease option to extend	options to extend certain of the leases up to 10.0 years
Lessee, Operating Lease, Existence of Option to Extend	true
Operating lease renewal term	10 years
Operating lease termination period	3 years
Number of operating lease terminate \| Lease	1
Operating lease expense	$ 1.1
Operating lease variable lease expense	0.5
Rent expenses		$ 1.2
Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received	0.8
Cash received for tenant improvement allowances	$ 0.3
Number of square feet \| ft²	19,867		100,000
Letter of credit			$ 2.1
Tenant improvement allowance	$ 0.6
Operating lease, lease not yet commenced lease liability	$ 100.1
Minimum
Lessee Lease Description [Line Items]
Operating lease remaining lease term	2 years 1 month 6 days
Operating lease,lease not yet commenced term of contract	5 years 2 months 12 days
Maximum
Lessee Lease Description [Line Items]
Operating lease remaining lease term	12 years 3 months 18 days
Operating lease,lease not yet commenced term of contract	12 years 8 months 12 days

Leases- Summary of Oher Information Related to Operating Lease (Details)	Mar. 31, 2020
Lessee Disclosure [Abstract]
Weighted-average remaining lease term (in years)	11 years 1 month 28 days
Weighted-average discount rate	4.50%

Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Lessee Disclosure [Abstract]
2020 (excluding the three months ended March 31, 2020)	$ 3,298
2021	5,123
2022	5,074
2023	4,364
2024	4,326
Thereafter	28,771
Total undiscounted lease payments	50,956
Imputed interest rate	(11,315)
Tenant improvement receivables	(1,594)
Total operating lease liabilities	38,047
Less: current portion	(1,502)
Operating lease liabilities, less current portion	$ 36,545

Shareholders' Equity - Additional Information (Details)			3 Months Ended	12 Months Ended
Shareholders' Equity - Additional Information (Details)	Jan. 01, 2020 shares	Jun. 30, 2019 shares	Mar. 31, 2020 Vote $ / shares shares	Dec. 31, 2014 $ / shares shares	Dec. 31, 2019 $ / shares shares	Mar. 31, 2019 shares	Dec. 31, 2018 shares
Class Of Stock [Line Items]
Preferred stock, shares authorized			10,000,000		10,000,000
Preferred stock, par value \| $ / shares			$ 0.0001		$ 0.0001
Preferred stock, shares outstanding			0		0
Common stock authorized			340,000,000		340,000,000
Common stock par value \| $ / shares			$ 0.0001		$ 0.0001
Common stock voting rights description			Holders of our common stock are entitled to one vote for each share of common stock held
Number of vote for each share \| Vote			1
Common stock outstanding			126,621,829		125,238,142
Warrants issued to purchase stock			56,875
Series C Convertible Preferred Stock
Class Of Stock [Line Items]
Warrants issued to purchase stock				56,875
Warrant exercisable term				7 years
Weighted-average exercise price of warrants \| $ / shares				$ 2.64
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Increase in share reserve	1,252,381
Maximum \| Employee Stock Purchase Plan
Class Of Stock [Line Items]
Percentage of annual increases in number of shares	1.00%
2019 Equity Incentive Plan
Class Of Stock [Line Items]
Increase in share reserve	6,261,907
2019 Equity Incentive Plan \| Maximum
Class Of Stock [Line Items]
Percentage of annual increases in number of shares	5.00%
Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of convertible preferred stock		93,039,737
Convertible preferred stock outstanding			0			93,023,694	92,790,094

Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)	Mar. 31, 2020 shares
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	39,786,801
Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	17,492,204
Grant \| 2019 Equity Incentive Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	19,433,424
Grant \| Employee Stock Purchase Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	2,804,298
Exercise of Common Stock Warrant
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	56,875

Equity Incentive Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average remaining contractual life options outstanding	7 years 2 months 12 days
Weighted-average remaining contractual life vested and exercisable options outstanding	5 years 9 months 18 days
Proceeds from exercise of stock options	$ 4,959	$ 130
Proceeds from settlement of stock option exercised in prior periods	$ 500
Weighted-average volatility	70.70%	64.40%
Share-based compensation expense	$ 4,675	$ 3,046
Unrecognized share-based compensation expense related to unvested stock options	$ 71,200
Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition	3 years 3 months 18 days
Option Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition	2 months 12 days
Unrecognized share-based compensation expense related to unvested RSUs	$ 100
Sequenta 2008 Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	0
2009 Equity Incentive Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	0
2009 Equity Incentive Plan \| Options \| Non Employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
2009 Equity Incentive Plan \| Options \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period	10 years
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	19,433,424,000		15,396,254,000
2019 Equity Incentive Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for issuance	22,025,259
2019 Equity Incentive Plan \| Options \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period	10 years
2019 Equity Incentive Plan \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation granted shares vested	2,250
Weighted-average grant date fair value per share	$ 41.63
Share-based compensation nonvested and outstanding shares	2,250		4,500
Weighted-average grant date fair value per share nonvested and outstanding	$ 41.63		$ 41.63

Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan	3 Months Ended
	Mar. 31, 2020 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Available for Grant, Outstanding, Beginning Balance	15,396,254,000
Shares Available for Grant, 2019 Plan reserve increase	6,261,907,000
Shares Available for Grant, Options and restricted stock units granted	(2,292,847,000)
Shares Available for Grant, Options and restricted stock units forfeited or cancelled	68,110,000
Shares Available for Grant, Outstanding, Ending Balance	19,433,424,000

Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding Options, Options outstanding, Beginning Balance	16,646,654
Shares Subject to Outstanding Options, Options granted	2,292,847
Shares Subject to Outstanding Options, Options forfeited or cancelled	(68,110)
Shares Subject to Outstanding Options, Options exercised	(1,381,437)
Shares Subject to Outstanding Options, Options outstanding, Ending Balance	17,489,954
Shares Subject to Outstanding Options, Options vested and exercisable	9,670,591
Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance	$ 6.14
Weighted Average Exercise Price per Share, Options granted	29.68
Weighted Average Exercise Price per Share, Options forfeited or cancelled	8.63
Weighted Average Exercise Price per Share, Options exercised	3.27
Weighted Average Exercise Price per Share, Options outstanding, Ending Balance	9.44
Weighted Average Exercise Price per Share, Options vested and exercisable	$ 5.03
Aggregate Intrinsic Value, Option outstanding	$ 329,432	$ 398,379
Aggregate Intrinsic Value, Options vested and exercisable	$ 220,010

Equity Incentive Plans - Summary of Estimated Fair Value of Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value		$ 7.80
Risk-free interest rate		2.50%
Risk-free interest rate, minimum	0.70%
Risk-free interest rate, maximum	1.70%
Expected volatility, minimum	70.50%	64.30%
Expected volatility, maximum	72.10%	65.50%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 17.68
Expected term (in years)	5 years 3 months 7 days	5 years 3 months 7 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 31.71
Expected term (in years)	6 years 29 days	6 years 29 days

Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 4,675	$ 3,046
Cost of Revenue
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	172	130
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	1,544	917
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	1,157	906
General and Administration
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 1,802	$ 1,093

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Effective tax benefit	$ 323,000	$ 0
CARES ACT 2020 aid net operating losses carryforward period	5 years

Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (31,403)	$ (18,386)
Fair value adjustments to redemption value for Series E-1 convertible preferred stock options		(254)
Net loss attributable to common shareholders	$ (31,403)	$ (18,640)
Weighted-average shares used in computing net loss per share	126,058,389	12,886,087
Net loss per share attributable to common shareholders, basic and diluted	$ (0.25)	$ (1.45)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	16,884,062	109,277,316
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		92,974,578
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	16,823,569	16,190,831
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	3,618
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	56,875	55,032
Convertible Preferred Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		56,875